BREAKING: National Gender Equity Group UltraViolet Responds to SCOTUS Stay on Abortion Pill Case

FOR IMMEDIATE RELEASE: Friday, April 21, 2023
CONTACT: Anna Zuccaro |

BREAKING: National Gender Equity Group UltraViolet Responds to SCOTUS Stay on Abortion Pill Case

Supreme Court issues a stay leaves mifepristone as FDA’s authority to approve abortion drug mifepristone is questioned

WASHINGTON, DC — Moments ago, the Supreme Court issued a stay on Alliance for Hippocratic Medicine v. FDA allowing mifepristone, an FDA approved abortion pill, to remain fully available while additional appeals are made.

The decision comes after an order last Friday, which temporarily ensured mifepristone would remain widely available as the Supreme Court considered whether to grant the Biden administration’s emergency request to preserve the Food and Drug Administration’s approval of the drug.

In response to the decision, Shaunna Thomas, co-founder and executive director of UltraViolet, a leading gender rights advocacy organization, issued the following statement:
“This case should never have been granted standing at all, let alone considered by SCOTUS. Today’s decision is the work of a lawless group of anti-abortion, anti-democracy extremists conspiring within and outside our government to ban abortion everywhere.

“The reality that millions of people may lose mifepristone access nationwide is still possible. Everyone who supports abortion rights and access to reproductive healthcare should know this decision puts our country in an even more precautionary position than after Roe v. Wade was overturned.

“In the meantime, we urge the Biden administration and state legislators to do everything in their power to preserve access to Mifepristone. We also urge all major pharmacy brands to publicly commit to making mifepristone available to every patient.”

In anticipation of the federal district court ruling in Amarillo, TX, UltraViolet called on:
Retail Pharmacies like Walgreens, CVS, Rite-Aid, Walmart, Costco, and Target to provide mifepristone to customers and release public statements about the safety and efficacy of the drug and brand commitments to provide it to their customers;
The FDA and the Biden Administration to ignore the ruling — a single federal district court judge should not have the power to halt a government agency’s authority, especially not over a safe, legal medication available for more than twenty years;
Governors to cut ties to pharmaceutical providers who refuse to dispense mifepristone, and for State Attorneys General to give assurances to providers that they will be protected from litigation if they continue to provide mifepristone;
All health insurance providers must cover abortion care, even in the face of this potential ban, and speak out against the ruling.
Last month, UltraViolet commissioned a mobile billboard in Phoenix, AZ at the American Pharmacists Association Conference, urging pharmacists to continue advocating for the protection of access to mifepristone.
# # #